drugset / Trial / NCT04762459
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
Phase 3
Enrolling by invitation
606 enrolled
Chinese Academy of Medical Sciences
GeneCast Biotechnology Co., Ltd. · collabJiangsu Hansoh Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open label, phase III study.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2026-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |